Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy.
The relapse rate of bladder cancer (transitional cell Ca) is said to be about 45%-80% even after tumor resection. Multidisciplinary treatment was designed and studied to prevent such recurrence. This treatment was designed to have three steps: induction, consolidation, and maintenance therapy. Following surgical tumor removal, OK-432 and Adriamycin (ADM) were administered as consolidation therapy, followed by administration of PSK and carboquone (CQ) in small amounts as maintenance therapy continuously for about 3 years, and the course was observed. In both consolidation and maintenance groups various non-specific immunoparameters were superior in groups receiving combined immunotherapeutic agents. Thus, the use of immunotherapeutic agents in combination with chemotherapeutic agents was considered to be effective. The 3-year recurrence rate was only 8% in the multidisciplinary treatment group, while that in the non-multidisciplinary treatment group was 61%. This approach, especially with chemoimmunotherapy (ADM and OK-432) as a consolidation therapeutic mode, is therefore considered to be useful for the prevention of recurrence.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001688:Biological Products / Q000008:administration & dosage*; D002225:Carbazilquinone / Q000008:administration & dosage; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D010844:Picibanil / Q000008:administration & dosage*; D011509:Proteoglycans / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality
D000276:Adjuvants, Immunologic; D001688:Biological Products; D002272:Carcinoembryonic Antigen; D007074:Immunoglobulin G; D011509:Proteoglycans; D002225:Carbazilquinone; D010844:Picibanil; C010770:polysaccharide-K; D004317:Doxorubicin